Jump to Main Contents

Home > Information

Information

Sep. 13, 2021
Webinar on Clinical Research with Guangxi, China
Aug. 24, 2021
Webinar with Guangxi, China
Aug. 16, 2021
Webinar with Neijiang, China
Jun. 30, 2021
Initiation of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan, SCRUM-Japan
May 17, 2021
"MONSTAR-SCREEN" has joined as an official member program in the International Cancer Genome Consortium Accelerating Research in Genomic Oncology (ICGC-ARGO)
May 14, 2021
NATIONAL CANCER CENTER AND EISAI COMMENCE JOINT RESEARCH AND DEVELOPMENT PROJECT “BASIC RESEARCH ON THE DRUG DISCOVERY AND DEVELOPMENT TO ACCELERATE DEVELOPMENT OF ANTICANCER DRUGS IN TREATMENT OF PATIENTS WITH RARE CANCERS AND REFRACTORY CANCERS”, USING PDX WITH HIGH PREDICTABILITY OF CLINICAL OUTCOMES, AND CANCER GENOME DATA
Feb. 2, 2021
Deep Vision: Near-Infrared Imaging and Machine Learning Can Identify Hidden Tumors
Oct. 22, 2020
Webinar with Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College
Oct. 6, 2020
Development of Precision Medicine for Gastrointestinal Cancers Utility of Liquid Biopsy in Genomic Analysis
Aug. 20, 2020
NCC joins GSK’s oncology development network
Jun. 22, 2020
National Cancer Center Japan and Mitsui Fudosan Agree on Accommodation Facility at the National Cancer Center Hospital East in Kashiwa-no-ha Smart City
Mar. 7, 2019
Kazakhstan Delegation visit
Nov. 19, 2018
Quickening the pace of new anti-cancer agents Attracting nanoparticles full of cancer drugs to the stroma of a tumour is proving key to new therapeutics.
Nov. 13, 2018
Hospital East honoured at ESMO
Aug. 8, 2018
Dr Masaaki Ito appointed Honorary Professor at China-Japan Friendship Hospital
Apr. 3, 2018
Advanced Medical Care Approval Received for Multiplex Gene Panel Testing
to Advancing Personalized Medicine
Mar. 13, 2018
SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood
Feb. 14, 2018
A secondary RET mutation in the activation loop conferring
resistance to vandetanib through allosteric effects